Onxeo_Onco

Onxeo is a biopharmaceutical company specialist in the development of oncology products (Euronext : $Onxeo)

[Onxeo_Onco @Onxeo_]

New preclinical data confirming AsiDNA™’s abilities to protect from #anticancer treatment toxicity and fight #tumor resistance presented during poster and oral sessions at the American Association for Cancer Research Annual Meeting (#AACR)
More info: https://t.co/XBvIFxo2LP

[Onxeo_Onco @Onxeo_]

Onxeo $ALONX appoints Dr. Shefali Agarwal as President and Chief Executive Officer

More information here👉https://t.co/yThoLOsGNn

[Onxeo_Onco @Onxeo_]

At #Onxeo,
#clinical-stage #biotechnology company developing innovative #oncology drugs targeting #tumor DNA Damage Response,
we support the #WorldCancerDay

https://t.co/owY7DF6O2E

[Onxeo_Onco @Onxeo_]

We participate in the DDR, ATR & PARP Inhibitors Summit 2022 !

Wael Jdey, Lead Scientist at #ONXEO will present today at 8AM EST and at 9:30AM EST

Click here for more info 👉 https://t.co/X0Tk86w2hM

#event #digitalevent #PARPinhibitors #Resistance

[Onxeo_Onco @Onxeo_]

AsiDNA™’s pioneering data highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions

Click here for more infos 👉 https://t.co/sDT9voCanp

#ONXEO #eacrAstraZeneca @AstraZeneca

[Onxeo_Onco @Onxeo_]

#Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector

More information 👉 https://t.co/t9wfMt9ndz

[Onxeo_Onco @Onxeo_]

#Onxeo Appoints Dr. Shefali Agarwal as Chairwoman of the Board !
More information here 👉 https://t.co/8QqX9P1PBE

[Onxeo_Onco @Onxeo_]

#Onxeo is pleased to announce its attendance at the Kepler Cheuvreux Digital Life Science Days

[Onxeo_Onco @Onxeo_]

#Onxeo Receives Notice of Allowance for a New Patent
Broadening the Protection of AsiDNA™ in combination
with a PARP Inhibitor in the United States until 2036
More informations 👉 https://t.co/7bWO9SrgDc

[Onxeo_Onco @Onxeo_]

#Onxeo Reports FYR 2020 and Provides Business Update: financial visibility until end-2022, enabling the expansion of clinical and industrial development of #AsiDNA™

[Onxeo_Onco @Onxeo_]

#Onxeo announces the #success of its Rights Issue
with €9.7 million raised !

[Onxeo_Onco @Onxeo_]

#Onxeo to Present New Preclinical Data at @AACR (American Association for Cancer Research) 2021 👉 https://t.co/xkDKuxBFAG

[Direct Dirigeants @DirectDirigeant]

Retrouvez l'#interview de Judith Greciet, Directrice Générale d'@Onxeo_ chez @B_SMART_TV concernant la levée de fonds d'#Onxeo 👇
https://t.co/8BaXD8YUNn
#BSmart #SmartBourse #finance #bourse

[Direct Dirigeants @DirectDirigeant]

Judith Greciet, Directrice Générale d'@Onxeo_ détaille les prochaines étapes majeures d'#Onxeo 👇

[Direct Dirigeants @DirectDirigeant]

Judith Greciet, Directrice Générale d'@Onxeo_ répond à une question concernant l'augmentation de capital en cours 👇

[Direct Dirigeants @DirectDirigeant]

[INTERVIEW]
Retrouvez Judith Greciet, Directrice Générale d'@Onxeo_, qui commente les récents développements d’#Onxeo et explique les raisons de l'augmentation de capital en cours ➡️ https://t.co/xRGXmJR52L
#Interview #Onxeo

[Direct Dirigeants @DirectDirigeant]

Pour la semaine nationale de lutte contre le #cancer, nous vous présentons @Onxeo_ ➡️ une #biotech qui conçoit et développe de nouveaux #médicaments contre le cancer en ciblant les fonctions de réparation de l'ADN des #tumeurs.
Plus d'infos 👉 https://t.co/j4DbSqWaHD

[Onxeo_Onco @Onxeo_]

#Onxeo launches a €9.3 million rights issue
For more information 👉 https://t.co/owY7DF6O2E

[Onxeo_Onco @Onxeo_]

#Onxeo is committed to women's health in the treatment of women's cancers.
#Revocan #Cancer #Oncology #8M2021 #WomensDay2021

[Onxeo_Onco @Onxeo_]

Learn how AsiDNA™ by @Onxeo_ fights #tumor persistent #cells that play a key role in resistance to targeted therapies and #cancer relapse
Watch the video 👉 https://t.co/lf4zgGrOBr

© Hanson Wade 2021 – posted with permission